Home › Asset managers › Compare 2024-2025 › Vanguard vs Fidelity
Vanguard 2024-2025 · Fidelity 2024-2025 · Download the item list (CSV)
| Common items | Same | Differ | Split (not in %) | Same position | Fund-level | |
|---|---|---|---|---|---|---|
| All ballot items | 104,601 | 95,503 | 4,347 | 4,751 | 95.6% | 94.3% |
| Board proposals | 83,560 | 75,723 | 3,819 | 4,018 | 95.2% | 93.8% |
| E&S shareholder proposals | 277 | 165 | 0 | 112 | 100.0% | 91.6% |
| Other items | 20,764 | 19,615 | 528 | 621 | 97.4% | 96.3% |
Everything Voted differently Split votes
All ballot items Board proposals E&S shareholder proposals Other items
7,837 items. “Voted differently”: each manager’s funds all voted one way, and the two ways differ. “Split”: at least one manager’s funds did not all vote the same way.
| Company | Meeting | Proposal | On the ballot from | Board recommended | Vanguard | Fidelity |
|---|---|---|---|---|---|---|
| COSCO SHIPPING ENERGY TRANSPORTATION CO. LTD. | April 11, 2025 | Approve Target Subscribers and Method of Subscription Capital Structure |
Board | For | FOR 5 funds |
AGAINST 6 funds |
| COSCO SHIPPING ENERGY TRANSPORTATION CO. LTD. | April 11, 2025 | Approve Undertakings to be Made by the Relevant Entities in Respect of the Measures on the Dilution of the Company's Current Return by the Proposed Issuance of A Shares to Specific Target Subscribers Capital Structure |
Board | For | FOR 5 funds |
AGAINST 6 funds |
| COSCO SHIPPING ENERGY TRANSPORTATION CO. LTD. | April 11, 2025 | Approve Validity Period of the Resolution Prior to the Issuance Capital Structure |
Board | For | FOR 5 funds |
AGAINST 6 funds |
| COSCO SHIPPING PORTS LTD. | May 20, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 1 fund |
| COSCO SHIPPING PORTS LTD. | May 20, 2025 | Authorize Reissuance of Repurchased Shares Capital Structure |
Board | For | FOR 6 funds |
AGAINST 1 fund |
| COSMAX INC. | March 27, 2025 | Approve Total Remuneration of Inside Directors and Outside Directors Compensation |
Board | For | AGAINST 6 funds |
FOR 3 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | ELECT NIALL DONNELLY AS EXECUTIVE DIRECTOR (CFO) Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | GRANT BOARD AUTHORITY TO ISSUE SHARES UP TO 10 PERCENT OF ISSUED CAPITAL FOR THE EMPLOYEE STOCK OWNERSHIP PLAN Capital Structure |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | REELECT ALESSANDRO DELLA CHA AS NON-EXECUTIVE DIRECTOR (CHAIRMAN) Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | REELECT JOHN O'DEA AS NON-EXECUTIVE DIRECTOR Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | REELECT MARIA GRAZIA RONCAROLO AS NON-EXECUTIVE DIRECTOR Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | REELECT MAURO SEVERINO AJANI AS NON-EXECUTIVE DIRECTOR Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMO PHARMACEUTICALS N.V. | May 30, 2025 | REELECT SILVANA PERRETTA AS NON-EXECUTIVE DIRECTOR Director Elections |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| COSMOS HEALTH INC. | November 19, 2024 | Election of Directors: Dr. Anastasios Aslidis Director Elections |
Board | For | WITHHOLD 1 fund |
FOR 4 funds |
| COSMOS HEALTH INC. | November 19, 2024 | Election of Directors: Dr. Manfred Ziegler Director Elections |
Board | For | WITHHOLD 1 fund |
FOR 4 funds |
| COSMOS HEALTH INC. | November 19, 2024 | Election of Directors: John J. Hoidas Director Elections |
Board | For | WITHHOLD 1 fund |
FOR 4 funds |
| COUNTRY GARDEN SERVICES HOLDINGS COMPANY LTD. | July 9, 2024 | Adopt 2024 Share Option Scheme and Related Transactions Compensation |
Board | For | FOR 6 funds |
AGAINST 3 funds |
| COUNTRY GARDEN SERVICES HOLDINGS COMPANY LTD. | July 9, 2024 | Approve Scheme Mandate Limit and Related Transactions Compensation |
Board | For | FOR 6 funds |
AGAINST 3 funds |
| COUNTRY GARDEN SERVICES HOLDINGS COMPANY LTD. | July 9, 2024 | Approve Service Provider Sublimit and Related Transactions Compensation |
Board | For | FOR 6 funds |
AGAINST 3 funds |
| COUNTRY GARDEN SERVICES HOLDINGS COMPANY LTD. | May 23, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights Capital Structure |
Board | For | FOR 7 funds |
AGAINST 3 funds |
| COUNTRY GARDEN SERVICES HOLDINGS COMPANY LTD. | May 23, 2025 | Authorize Reissuance of Repurchased Shares Capital Structure |
Board | For | FOR 7 funds |
AGAINST 3 funds |
| COWELL E HOLDINGS INC. | May 29, 2025 | Authorize Reissuance of Repurchased Shares Capital Structure |
Board | For | FOR 5 funds |
AGAINST 4 funds |
| CP ALL PUBLIC COMPANY LTD. | April 25, 2025 | Elect Dumrongsak Kittiprapas as Director Director Elections |
Board | For | FOR 5 funds |
AGAINST 9 funds |
| CPI EUROPE AG | May 20, 2025 | Approve Issuance of Warrants/Bonds with Warrants Attached/Convertible Bonds without Preemptive Rights up to Aggregate Nominal Amount of EUR 613.1 Million; Approve Creation of EUR 13.9 Million Pool of Capital to Guarantee Conversion Rights Capital Structure |
Board | For | FOR 7 funds |
AGAINST 2 funds |
| CRAWFORD & CO. | May 8, 2025 | Proposal to elect the nine (9) nominees listed below as Directors: R. Patel Director Elections |
Board | For | FOR 3 funds |
WITHHOLD 3 funds |
| CRAYON GROUP HOLDING AS | May 7, 2025 | Approve Remuneration Statement Compensation |
Board | For | AGAINST 6 funds |
FOR 2 funds |
| CREATE SD HOLDINGS CO. LTD. | August 23, 2024 | Elect Director Hirose, Taizo Director Elections |
Board | For | AGAINST 7 funds |
FOR 4 funds |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC. | July 19, 2024 | To approve, on a nonbinding advisory basis, the compensation of our named executive officers. Say-on-Pay |
Board | For | FOR 1 fund |
AGAINST 2 funds |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC. | May 5, 2025 | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercise in full of warrants to purchase an aggregate of 1,799,774 shares of our Common Stock that we issued on March 6, 2025. Capital Structure |
Board | For | FOR 1 fund |
AGAINST 3 funds |
| CREDITACCESS GRAMEEN LTD. | August 12, 2024 | Amend CAGL Employees Stock Option Plan-2011 Compensation |
Board | For | FOR 5 funds |
AGAINST 1 fund |
| CREDITO EMILIANO SPA | April 30, 2025 | Approve Second Section of the Remuneration Report Compensation |
Board | For | AGAINST 6 funds |
FOR 2 funds |
| CREEK & RIVER CO. LTD. | May 29, 2025 | Elect Director Ikawa, Yukihiro Director Elections |
Board | For | AGAINST 1 fund |
FOR 3 funds |
| CREXENDO INC. | August 7, 2024 | Election on Directors: Jeffrey P. Bash Director Elections |
Board | For | AGAINST 2 funds |
FOR 4 funds |
| CRICUT INC. | May 28, 2025 | Election of Directors: Jason Makler Director Elections |
Board | For | FOR 12 funds |
WITHHOLD 16 funds |
| CRISPR THERAPEUTICS AG | June 5, 2025 | 4.f Re-election of John T. Greene Director Elections |
Board | For | FOR 4 funds |
AGAINST 4 funds |
| CRISPR THERAPEUTICS AG | June 5, 2025 | 5.c Re-election of John T. Greene Director Elections |
Board | For | FOR 4 funds |
AGAINST 4 funds |
| CRISPR THERAPEUTICS AG | June 5, 2025 | 6.c Binding vote on maximum non-performance-related compensation for members of the Executive Committee from July 1, 2025 to June 30, 2026. Compensation |
Board | For | FOR 4 funds |
AGAINST 4 funds |
| CRISPR THERAPEUTICS AG | June 5, 2025 | 6.d Binding vote on maximum variable compensation for members of the Executive Committee for the current year ending December 31, 2025. Compensation |
Board | For | FOR 4 funds |
AGAINST 4 funds |
| CROMWELL PROPERTY GROUP | November 29, 2024 | Approve Remuneration Report Compensation |
Board | For | FOR 7 funds |
AGAINST 2 funds |
| CRRC CORPORATION LTD. | June 18, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights for Additional A Shares and H Shares Capital Structure |
Board | For | FOR 6 funds |
AGAINST 7 funds |
| CRYO-CELL INTERNATIONAL INC. | October 29, 2024 | Election of Directors: Daniel Mizrahi Director Elections |
Board | For | WITHHOLD 2 funds |
FOR 3 funds |
| CRYO-CELL INTERNATIONAL INC. | October 29, 2024 | Election of Directors: David Portnoy Director Elections |
Board | For | WITHHOLD 2 funds |
FOR 3 funds |
| CRYO-CELL INTERNATIONAL INC. | October 29, 2024 | Election of Directors: Mark Portnoy Director Elections |
Board | For | WITHHOLD 2 funds |
FOR 3 funds |
| CS WIND CORP. | March 26, 2025 | Approve Total Remuneration of Inside Directors and Outside Directors Compensation |
Board | For | AGAINST 6 funds |
FOR 4 funds |
| CSI SOLAR CO. LTD. | May 28, 2025 | Approve Remuneration of Directors and Senior Management Compensation |
Board | For | AGAINST 4 funds |
FOR 5 funds |
| CSI SOLAR CO. LTD. | May 28, 2025 | Approve Remuneration of Supervisors Compensation |
Board | For | AGAINST 4 funds |
FOR 5 funds |
| CSP INC. | February 4, 2025 | The approval of the 2025 CSP Inc. Stock Incentive Plan. Compensation |
Board | For | FOR 4 funds |
AGAINST 4 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Attribution of Profit and Loss During the Transition Period Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Audit Report, Pro Forma Review Report and Valuation Report in Relation to the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Authorization of the Board and Its Authorized Persons to Handle All Related Matters Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Completeness and Compliance of Implementation of Legal Proceedings of the Transaction and Validity of the Submitted Legal Documents Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Confidentiality Measures and Confidentiality System Adopted for This Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Description of the Basis and Fairness and Reasonableness of the Pricing of the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Distribution Arrangement of Undistributed Earnings Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Fluctuation of the Company's Stock Price Before the Release of Information on This Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Impact of Dilution of Current Returns on Major Financial Indicators, the Relevant Measures to be Taken and Commitment from Relevant Parties Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Independence of Appraiser, the Validity of Hypothesis, the Relevance of Valuation Method and Purpose and Approach as Well as the Fairness of Pricing Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Amount Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Amount and Number of Issues Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Manner and Target Subscribers Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Issue Type, Par Value and Listing Location Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Lock-Up Period Arrangement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Overall Plan Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Performance Commitment and Compensation Arrangement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Pricing Reference Date and Issue Price Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Purchases and Sales of Assets in the Twelve Months Prior to the Transaction Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Report (Draft) and Summary on Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds and Related Party Transactions Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Report on the Usage of Previously Raised Funds Capital Structure |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Resolution Validity Period Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Signing of Conditional Agreement to the Issuance of Shares and Acquisition by Cash as well as Performance Compensation Agreement Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Target Assets Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies With Article 18 and 21 of the Measures for the Continuous Supervision of ChiNext Listed Companies (Trial) and Article 8 of the Shenzhen Stock Exchange Listed Company Major Asset Restructuring Review Rules Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies With Article 4 of Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructuring Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies with Articles 11 and 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Complies with the Relevant Provisions of the Administrative Measures for the Registration of Securities Issuance of Listed Companies Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Constitute as Major Asset Restructuring and Does Not Constitute as Restructuring and Listing Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Parties Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Transaction Price and Payment Method Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve Use of Proceeds Capital Structure |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve the Company's Plan for Issuance of Shares and Acquisition by Cash as Well as Raising Supporting Funds Complies with Relevant Laws and Regulations Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CSPC INNOVATION PHARMACEUTICAL CO. LTD. | October 31, 2024 | Approve the Relevant Entity of Transaction Does Not Exist in Article 12 of Listed Company Supervision Guidelines No. 7 and Article 30 of the Guidelines for Self-regulatory Supervision No. 8 (Revised in 2023) Extraordinary Transactions |
Board | For | FOR 4 funds |
AGAINST 6 funds |
| CTCI CORP. | May 28, 2025 | Approve Issuance of Shares via a Private Placement Capital Structure |
Board | For | AGAINST 4 funds |
FOR 2 funds |
| CTS CO. LTD. | June 20, 2025 | Elect Director and Audit Committee Member Hirano, Seiichi Director Elections |
Board | For | FOR 5 funds |
AGAINST 4 funds |
| CTS CO. LTD. | June 20, 2025 | Elect Director and Audit Committee Member Yokoyama, Takashi Director Elections |
Board | For | FOR 5 funds |
AGAINST 4 funds |
| CUSTOM TRU | June 12, 2025 | To elect each of the four Class C directors to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified: Fred Ross Director Elections |
Board | Not determined | WITHHOLD 9 funds |
FOR 12 funds |
| CUTERA INC. | July 15, 2024 | Approval of the amendment of outstanding stock options to reduce the exercise price per share to the closing price on the date of the Annual Meeting. Compensation |
Board | For | AGAINST 9 funds |
FOR 8 funds |
| CXAPP INC. | May 20, 2025 | To elect Camillo Martino as a Class II director to serve until the annual meeting following the fiscal year ending December 31, 2027, or until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Director Elections |
Board | For | AGAINST 2 funds |
FOR 4 funds |
| CYBERARK SOFTWARE LTD. | June 24, 2025 | To approve the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31, 2025, and until the Company's 2026 annual general meeting of shareholders, and to authorize the Board to fix such accounting firm's annual compensation. Audit-related |
Board | For | AGAINST 1 fund |
FOR 1 fund |
| CYBOZU INC. | March 30, 2025 | Appoint Statutory Auditor Ogawa, Yoshitatsu Compensation |
Board | For | FOR 6 funds |
AGAINST 1 fund |
| CYCLACEL PHARMACEUTICALS INC. | February 6, 2025 | The approval of an amendment to the Certificate to increase the number of authorized shares of Common Stock from 100,000,000 shares to 250,000,000 shares, which number would not be adjusted as a result of the Reverse Stock Split Amendment, if such amendment is approved. Capital Structure |
Board | For | AGAINST 1 fund |
FOR 2 funds |
| CYNGN INC. | January 30, 2025 | Approval of an amendment to the Company's Certificate of Incorporation to increase the number of authorized common stock from 200,000,000 to 400,000,000 shares Capital Structure |
Board | For | AGAINST 1 fund |
FOR 3 funds |
| D'IETEREN GROUP | December 6, 2024 | Approve Dividends Capital Structure |
Board | For | FOR 6 funds |
AGAINST 10 funds |
| DAEJOO ELECTRONIC MATERIALS CO. LTD. | March 26, 2025 | Approve Total Remuneration of Inside Directors and Outside Directors Compensation |
Board | For | AGAINST 6 funds |
FOR 3 funds |
| DAH SING BANKING GROUP LTD. | May 30, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights Capital Structure |
Board | For | FOR 7 funds |
AGAINST 1 fund |
| DAH SING FINANCIAL HOLDINGS LTD. | May 30, 2025 | Approve Issuance of Equity or Equity-Linked Securities without Preemptive Rights Capital Structure |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| DAH SING FINANCIAL HOLDINGS LTD. | May 30, 2025 | Authorize Reissuance of Repurchased Shares Capital Structure |
Board | For | FOR 6 funds |
AGAINST 2 funds |
| DAIDO STEEL CO. LTD. | June 25, 2025 | Elect Director and Audit Committee Member Niwa, Tetsuya Director Elections |
Board | For | AGAINST 6 funds |
FOR 3 funds |
| DAIEI KANKYO CO. LTD. | June 26, 2025 | Elect Director Kaneko, Fumio Director Elections |
Board | For | AGAINST 6 funds |
FOR 4 funds |
| DAIHEN CORP. | June 26, 2025 | Appoint Statutory Auditor Morimoto, Keiki Compensation |
Board | For | AGAINST 6 funds |
FOR 2 funds |
| DAIKOKUTENBUSSAN CO. LTD. | August 22, 2024 | Elect Director Oga, Shoji Director Elections |
Board | For | FOR 5 funds |
AGAINST 4 funds |
← Previous Page 10 of 79 Next →
How items are matched and positions counted: see the comparison table and the methodology. Built October 25, 2026 from SEC Form N-PX filings.